OTC Markets OTCPK - Delayed Quote USD

Kuros Biosciences AG (CSBTF)

26.07

0.00

(0.00%)

At close: January 17 at 3:00:00 PM EST

Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement with the Medtronic Spinal Division

Kuros Biosciences USA Inc., ("Kuros"), a wholly owned subsidiary of Kuros Biosciences AG, a global leader in advanced musculoskeletal bone healing technologies, today announced a strategic five-year, exclusive sales agency agreement with Medtronic, ...

ACCESS Newswire 11 days ago

CSBTF
0.00%
Kuros Biosciences Expands into Extremities Markets

Commercial Highlights Appointment of Jantzen Cole as Vice President of Market Development, Extremities, to drive the Company's acceleration beyond the spine market Strategic expansion opens new addressable market opportunity estimated at $1 billion ...

ACCESS Newswire last month

CSBTF
0.00%
Kuros Reports 149% Increase in Direct MagnetOs Sales and Exceeds Cash Flow Breakeven in the First Nine Months of 2024

Financial Highlights Direct MagnetOsTM sales rose by 149% to CHF 50.6 million in the first nine months of 2024, from CHF 20.4 million in the same period in 2023 Total Kuros Medical Devices segment sales accelerated to CHF 51.1 million in Q3 2024 from ...

ACCESS Newswire 3 months ago

CSBTF
0.00%
Kuros Biosciences Reports First Half of 2024 Results

Financial Highlights Direct MagnetOs™ sales increased by 159% to CHF 31.6 million from CHF 12.2 million in H1 2023; this corresponds to a sequential increase of 62% or CHF 12.1 million over H2 2023 Total Kuros Medical Devices segment sales increased ...

ACCESS Newswire 5 months ago

CSBTF
0.00%
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft

ZURICH, SWITZERLAND / ACCESSWIRE / June 25, 2024 / Kuros Biosciences, a leader in next generation bone healing technologies, today announced the publication of a peer-reviewed manuscript that details the clinical data of its MAXA Level 1 prospective, ...

ACCESS Newswire 6 months ago

CSBTF
0.00%
Kuros Reports Corporate Highlights as of Q1 2024 Including Increase in Direct MagnetOsTM Sales

Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023; this corresponds to a sequential increase of 21.9% or CHF 2.5 million over Q4 2023 Total Kuros Medical Devices segment sales accelerated ...

ACCESS Newswire 8 months ago

CSBTF
0.00%
Annual General Meeting of Kuros Biosciences Approves All Resolutions

ZURICH, SWITZERLAND / ACCESSWIRE / April 17, 2024 / Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the Annual Financial ...

ACCESS Newswire 8 months ago

CSBTF
0.00%
Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023

Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million in 2022. Total medical device sales accelerated by 153% from CHF 13.3 million in 2022 to CHF 33.6 million in 2023 The Medical Devices ...

ACCESS Newswire 10 months ago

CSBTF
0.00%
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

- Company to host conference call and webcast on March 13, 2024, at 3pm CET/10am US EST SCHLIEREN (ZURICH), SWITZERLAND / ACCESSWIRE / March 8, 2024 / Kuros Biosciences ("Kuros" or "the Company"), a leader in next-generation bone graft technologies, ...

ACCESS Newswire 10 months ago

CSBTF
0.00%
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

ZURICH, SWITZERLAND / ACCESSWIRE / February 1, 2024 / Kuros Biosciences ("Kuros" or "the Company"), a leader in next generation bone graft technologies, today announced it will present at the CG 2024 Musculoskeletal Conference, to be held in San Francisco ...

ACCESS Newswire 11 months ago

CSBTF
0.00%
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand

MagnetOs ™ Granules becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for interbody use Kuros continues expansion of the MagnetOs franchise with launch of MagnetOs Granules and MagnetOs Putty in New Zealand via ...

ACCESS Newswire 11 months ago

CSBTF
0.00%

Performance Overview

Return	CSBTF	MSCI WORLD
YTD	+15.51%	+1.59%
1-Year	+391.89%	+20.08%
3-Year	+922.35%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kuros Biosciences AG (CSBTF)

Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement with the Medtronic Spinal Division

Kuros Biosciences Expands into Extremities Markets

Kuros Reports 149% Increase in Direct MagnetOs Sales and Exceeds Cash Flow Breakeven in the First Nine Months of 2024

Kuros Biosciences Reports First Half of 2024 Results

Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft

Kuros Reports Corporate Highlights as of Q1 2024 Including Increase in Direct MagnetOsTM Sales

Annual General Meeting of Kuros Biosciences Approves All Resolutions

Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023

Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand

Performance Overview